Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.

Thumbnail
View/Open
Accepted version (1.501Mb)
Publication Date
2020-01-10
ICR Author
Jones, Chris
Mackay, Alan
Author
Rodriguez Gutierrez, D
Jones, C
Varlet, P
Mackay, A
Warren, D
Warmuth-Metz, M
Sánchez Aliaga, E
Calmon, R
Hargrave, DR
Cañete, A
Massimino, M
Azizi, AA
Le Deley, M-C
Saran, F
Rousseau, RF
Zahlmann, G
Garcia, J
Vassal, G
Grill, J
Morgan, PS
Jaspan, T
Type
Journal Article
Metadata
Show full item record
Abstract
BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathological and molecular data. METHODS:Radiological, pathological and molecular data were correlated with trial clinical information to retrospectively re-evaluate event free and overall survival. RESULTS:One-hundred thirteen patients were randomized to the RT/TMZ arm (n =54) or the RT/TMZ+BEV (BEV arm; n =59). The tumor arose in the cerebral hemispheres in 68 patients (Cerebral group) and a midline location in 45 cases (Midline group). Pathological diagnosis was available in all cases and molecular data in 86/113. H3 K27M histone mutations were present in 23/32 Midline cases and H3 G34R/V mutations in 7/54 Cerebral cases. Total/near-total resection occurred in 44/68 (65%) Cerebral cases but only 5/45 (11%) Midline cases (p <0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) at relapse were more frequent in Midline (17/45) than Cerebral tumors (10/68, p <0.05). Mean OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (p <0.05). Pseudoprogression occurred in 8/111 (6.2%) cases. CONCLUSIONS:This study has shown that the poor outcome of midline tumors (compared to cerebral) may be related to 1) lesser surgical resection, 2) H3 K27M histone mutations, and 3) higher leptomeningeal dissemination.
URL
https://repository.icr.ac.uk/handle/internal/3581
Collections
  • Cancer Therapeutics
  • Molecular Pathology
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1158/1078-0432.ccr-19-3154
Research team
Glioma Team
Language
eng
Date accepted
2020-01-07
License start date
2020-01-10
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.